Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,918Revenue (TTM) $M165Net Margin (%)-92.8Altman Z-Score-0.9
Enterprise Value $M2,778EPS (TTM) $-1.1Operating Margin %-68.2Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.0Pre-tax Margin (%)-92.3Higher ROA y-yN
Price/Book33.010-y EBITDA Growth Rate %--Quick Ratio5.8Cash flow > EarningsY
Price/Sales15.75-y EBITDA Growth Rate %-25.3Current Ratio5.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-31.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M154ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with NKTR

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NKTR is held by these investors:



NKTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CHESS ROBERTDirector 2017-04-17Sell5,000$18.721.34view
Lingnau LutzDirector 2017-04-07Sell7,000$20.05-5.39view
KUEBLER CHRISTOPHER ADirector 2017-04-05Sell15,000$21.88-13.3view
Doberstein Stephen KSVP & Chief Scientific Officer 2017-04-05Sell100,000$21.7-12.58view
Hora ManinderSVP Pharma Dev & Mfg Ops 2017-04-05Sell180,000$21.7-12.58view
Thomsen Jillian B.SVP & Chief Accounting Officer 2017-03-20Sell112,500$19.69-3.66view
CHESS ROBERTDirector 2017-03-14Sell5,000$15.4123.1view
Labrucherie Gil MSVP & CFO 2017-03-03Sell200,000$15.1625.13view
Lingnau LutzDirector 2017-02-21Sell30,000$13.0845.03view
Doberstein Stephen KSVP & Chief Scientific Officer 2017-02-16Sell1,261$13.1444.37view

Quarterly/Annual Reports about NKTR:

News about NKTR:

Articles On GuruFocus.com
Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting Apr 20 2017 
Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American A Apr 04 2017 
4 Biotech Stocks to Watch Mar 22 2017 
Weekly CEO Sales Highlight: Monolithic Power Systems, Five Prime Therapeutics, Nektar Therapeutics Feb 15 2016 
Weekly CEO Sells Highlight: Cadence Design Systems Inc., Nektar Therapeutics Inc., Netflix Inc., Pho Sep 27 2015 
Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Biotech Surge: How To Survive In A Volatile Market Apr 28 2017
Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting Apr 20 2017
How Nektar Therapeutics' Latest Drug Could Shake Up the Market for Pain Medicine Apr 19 2017
Can Drugmakers Cure the Opioid Crisis? Apr 18 2017
Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology Apr 10 2017
The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar... Apr 07 2017
Nektar Therapeutics (NKTR) Up 57.2% Since Earnings Report: Can It Continue? Apr 07 2017
3 of the Best & Worst Performing Drug Stocks of Q1 Apr 06 2017
Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American... Apr 04 2017
Cramer's lightning round: If we get two rate hikes, this stock's a good buy Apr 03 2017
3 Revolutionary Drugs for Chronic Pain Mar 30 2017
Western Digital, Nektar Therapeutics And Two More Stocks Breaking Out Mar 30 2017
Harry Boxer’s five technology and biotechnology stocks to watch Mar 29 2017
Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell... Mar 27 2017
Trump is tapping Chris Christie to tackle the opioid epidemic — here's a fix scientists hope he'll... Mar 27 2017
Could Nektar Therapeutics Be Worth More? Mar 23 2017
Nektar Therapeutics (NKTR): Here’s What Just Happened Mar 21 2017
Nektar's Pain Drug Positive in Phase III Study; Shares Gain Mar 21 2017
Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News Mar 21 2017
After-hours buzz: ESPR, NKTR, MMSI & more Mar 20 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)